Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Feature|Articles|August 20, 2025
- Pharmaceutical Executive: August 2025
- Volume 45
- Issue 6
2025 Emerging Pharma Leaders
Author(s)Mike Hollan
Listen
0:00 / 0:00
Pharm Exec unveils its new slate of rising leaders in the biopharma industry—profiling the stories of five executives steering innovative scientific and strategic pursuits in R&D, market access, and patient support.
Advertisement
Follow the links below to read about each selection:
(In alphabetical order)
*These five individuals were chosen from a pool of nominations by the Pharmaceutical Executive Editorial staff. Selections were based on a number of criteria and review of professional accomplishments and progression of responsibilities in line with those executives inhabiting key “c-suite” functions.
Articles in this issue
about 1 year ago
The CAR-T Climbabout 1 year ago
An RNA-Guided Pathabout 1 year ago
Acceleration and Ambitionabout 1 year ago
Driving Disruption in Deliveryabout 1 year ago
Building Promise from Precisionabout 1 year ago
Determined Problem-Solverabout 1 year ago
Direct-to-Consumer Prescription Care Comes of Ageabout 1 year ago
How to Get Product Iteration Right in HealthcareAdvertisement
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Caribou Biosciences is discontinuing its two allogeneic CAR-T programs and exploring strategic alternatives to maximize shareholder value.
CORXEL’s chief medical value discusses how GLP-1s are becoming a chronic disease platform.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
Why effective RWD linkage starts with a specific research objective — and how tokenization, clean rooms, and AI make it possible.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
2
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
3
The Most Important Lessons Learned from Building CGT Supply Chains: LogiPharma 2026
4
Viatris Acquires Pacira BioSciences for $1.65 Billion
5